Mergers & Acquisitions Modeling

Introduction

You're preparing Mergers & Acquisitions (M&A) models to size deals, test scenarios, and guide board votes - models turn strategy into numbers; be concise and decision-ready. Clarify the objective up front: are you looking to buy growth (accelerate revenue), buy capabilities (tech, IP, talent), consolidate market share (roll-up synergies and pricing power), or pursue financial engineering (EPS accretion, tax or balance-sheet gains). Define the model scope: target profile (revenue, margin, growth), acquirer type (strategic vs private equity), deal timeline (LOI to close typically 90-180 days), and materiality thresholds (e.g., deal value > 5% of acquirer EBITDA or > $50m). Here's the quick math - a $200m purchase equals ~5% of a buyer with $4bn EBITDA, so integration spend or a 6-12 month revenue lag can flip accretion to dilution; what this estimate hides is integration timing and execution risk. Corp Dev: build a 3-scenario model (base/upside/downside) with sensitivity to synergies and close timing by Friday - this will defintely clarify trade-offs.

Key Takeaways

• Clarify deal objective and scope up front: buy growth, capabilities, market share, or financial engineering; define target profile, acquirer type, timeline, and materiality thresholds.
• Deliver a 3‑scenario model (base/upside/downside) with sensitivity to synergies and close timing to surface key trade‑offs and execution risk.
• Value with three pillars-DCF (explicit 5-10y + terminal), comps, and precedents-adjusting for control premia, timing, and synergies.
• Model transaction mechanics end‑to‑end: EV calculation, purchase price allocation, financing schedule, pro‑forma financials, and accretion/dilution analysis across price, synergies, and cost of debt.
• Prioritize due diligence and integration planning (QoE, working capital, tax, regulatory, retention); present decision‑ready outputs (valuation range, accretion matrix, KPIs, and sensitivity decks).

Deal rationale and transaction types

You're sizing deals and deciding how to pay for them - the quick takeaway: map every strategic claim (growth, cost, IP) to a dollar and a timing profile, then pick the legal and payment form that preserves value and limits downside.

Map strategic drivers: revenue synergies, cost synergies, geographic expansion, tech/IP capture

One-liner: attach a numeric line item to each strategic driver so the board sees who pays for what and when.

Start by listing discrete drivers and the mechanism that creates cash: cross-sell lifts revenue, back-office consolidation reduces operating expense, new geographies add incremental customers, and acquired IP lowers future R&D or creates pricing power. For each driver, build a 3-5 year revenue and cost waterfall.

• Estimate baseline FY2025 metrics for the target: revenue, gross margin, and EBITDA.
• Project retention and conversion rates: assume conservative capture (example: cross-sell capture of 5-10% of FY2025 revenue over three years).
• Phasing: model realization cadence (example: 25% of run-rate synergies in year 1; 60% in year 2; full run-rate in year 3).
• Separate one-time integration costs: HR, IT, legal, and rebranding; assume one-time costs equal to 10-30% of first-year run-rate synergies.

Example quick math: target FY2025 revenue $300m, cross-sell capture 5% → incremental revenue $15m by year 3; at 20% margin that's $3m incremental EBITDA. What this estimate hides: customer churn, lost contracts, or salesforce execution risk - defintely stress-test a 50% realization case.

Best practices: require seller-level detail (customer cohorts, contract expiries), tie revenue synergies to retention metrics, and lock cost synergy assumptions to concrete line-item reductions (headcount, facilities, vendors).

Choose structure: stock purchase, asset purchase, statutory merger, tender offer

One-liner: the legal form changes tax outcomes, liability exposure, and accounting - pick based on tax attributes and leftover legal risk.

Define the options briefly and the practical implications.

• Stock purchase - buyer acquires shares; seller keeps capital gains tax character; buyer inherits historic liabilities and tax attributes.
• Asset purchase - buyer picks assets and liabilities; allows tax basis step-up (useful when you want deductible depreciation) but sellers may face double taxation if a C-corp.
• Statutory merger - streamlined transfer for public companies; legal successor inherits liabilities; mechanics vary by state and country law.
• Tender offer - direct to shareholders; faster in market deals but subject to regulatory timing and minimum tender conditions.

Practical steps: run a target-level tax model, legal liability heat map, and valuation under each structure. Example tax impact: a $200m basis step-up amortized over 20 years at a 21% federal tax rate yields an annual tax shield of $2.1m (that's $200m / 20 21%).

Negotiation levers: escrow size (commonly 5-10% of purchase price for 12-24 months), reps & warranties insurance to cap seller liability, and explicit carve-outs for contingent liabilities. Best practice: involve tax and litigation counsel before term sheet signing; structure should protect against tail liabilities and preserve usable tax shields.

Consider purchase price mechanics: cash, stock, debt, contingent consideration; and control premiums

One-liner: price level and payment mix determine cash needs, dilution, and incentives - model each mix to show board-level trade-offs.

For payment mix, evaluate three constraints: acquirer liquidity, share-price dilution, and tax implications. Common mixes: cash-heavy for certainty, stock to preserve cash, debt to amplify returns but increase leverage, and earnouts (contingent consideration) to bridge valuation gaps.

• Run a cash-flow and leverage impact for each financing mix; include interest at the syndicate rate and covenant tests.
• Design earnouts with clear metrics (EBITDA or revenue), caps, and time windows (commonly 2-3 years); avoid subjective milestones.
• Model accounting: stock issuance causes dilution; debt increases interest expense and can make near-term EPS accretion look worse despite higher IRR.

Example deal math: implied EV from comps = EV/EBITDA 8x on target FY2025 EBITDA $60m → implied EV $480m. Apply a 30% control premium → offer EV $624m. Financing split example: 60% cash = $374.4m, 30% stock = $187.2m, 10% earnout = $62.4m. What this hides: the premium often bakes in expected synergies; if synergies under-deliver you've effectively overpaid.

Control premiums guidance: expect 20-40% in many strategic deals; adjust up for scarce IP or vertical consolidation, and down for highly cyclical sectors. Steps to set premium: start from a 30-day VWAP (or recent private deal comps), layer strategic value you can demonstrably capture, and stress-test the price under 50% synergy realization.

Best practices: present the board with a matrix showing cash required, post-deal leverage, EPS accretion/dilution by year, and sensitivity to a 25%, 50%, and 75% realization of synergies. Include escrow and indemnity scenarios to quantify downside recovery.

Next step: Finance: build a base-case deal model using FY2025 target metrics and three sensitivity cases by Thursday; M&A lead: coordinate target DD package and seller financials.

Valuation approaches and inputs

You're building a deal model to set price ranges and guide the board - short takeaway: triangulate value with a DCF, comps, and precedents, then weight them by data quality and deal type.

Discounted Cash Flow (DCF): forecast, terminal, and WACC

One-liner: DCF converts operating plans into a present value; get the forecast and discount rate right or the rest is noise.

Steps to build a usable DCF

• Project explicit cash flows for 5-10 years depending on visibility.
• Forecast revenue drivers (price, volume, mix), gross margin, S,G&A, EBITDA, capex, and working capital changes.
• Derive free cash flow to firm (FCFF): operating income less taxes, plus D&A, minus capex and ΔNWC.
• Choose a terminal approach: Gordon growth (perpetuity) or exit multiple; typical terminal growth for mature US businesses: 2-3%.
• Compute WACC (weighted average cost of capital): cost of equity via CAPM, cost of debt after tax, apply target capital structure.

Practical WACC example (illustrative): assume 10‑year Treasury ~4.5%, equity risk premium ~5.5%, beta 1.1 → cost of equity ≈ 10.6%; cost of debt pre-tax ~6.0%, tax rate 21% → after-tax debt ~4.7%; with a 70/30 equity/debt mix → WACC ≈ 8.8%. Here's the quick math: WACC = 0.710.6% + 0.36.0%(1-21%). What this estimate hides: changes in ERP, beta, or capital structure move WACC by hundreds of bps, which dramatically shifts valuation.

Best practices

• Base projections on bottom-up drivers and run a sanity check against commodity/top‑down growth.
• Model multiple scenarios: base, downside, upside; keep assumptions transparent by line item.
• Cap terminal multiple to market reality; don't assume perpetually improving margins.

Comparable companies (comps): selecting peers and multiples

One-liner: comps anchor market sentiment - pick peers by economics, not ticker proximity.

Selection and normalization steps

• Screen peers by industry code, revenue growth, margin profile, and business mix (recurring vs transactional).
• Use last twelve months (LTM) and forward (FY+1) metrics: revenue, EBITDA, EPS, and capex intensity.
• Clean one-offs: adjust for restructuring, non‑recurring legal or tax items so multiples compare apples to apples.

Multiples and application

• Primary anchors: EV/EBITDA, EV/Revenue, and P/E.
• Match multiple to lifecycle: high-growth SaaS leans EV/Revenue; stable industrials lean EV/EBITDA.
• Use median and quartiles; create sensitivity table across the 25th-75th percentiles.

Concrete examples (illustrative): SaaS peers often trade EV/Revenue ~6-12x, mature industrials EV/EBITDA ~7-11x. Weight comps higher when public comparables are numerous and the business mix aligns closely.

Precedent transactions: control premiums, timing, and synergy adjustments

One-liner: precedents show what acquirers actually paid - but adjust for synergies and market moves.

How to pick and normalize precedents

• Limit to recent, comparable deals (sector, size, geography) - prioritize transactions within the last 18-36 months.
• Extract transaction multiples on LTM EBITDA and revenue; note announced vs. closed deals and whether disclosed multiples include synergies.
• Normalize for non-operating items, one-offs, and different accounting conventions.

Adjustments to convert precedent multiples into a bid range

• Account for control premium: plan for a premium of roughly 20-40% versus pre-deal trading price in many strategic deals; calibrate by sector and concentration.
• Adjust for announced synergies: if precedent included buyer synergies, either subtract an estimated synergy value or apply a discount for execution risk.
• Bring older transactions to present value: adjust multiples for market multiple shifts or convert synergy streams into NPV at an appropriate discount rate.

Quick calculation example (illustrative): target LTM EBITDA $80m, precedent median EV/EBITDA = 9x → EV = $720m; net debt = $100m → implied equity value = $620m. Divide by shares to get per-share bid. Defintely run sensitivity across ±20% multiples and ±50% synergy realization to test robustness.

Weighting guidance

• Use DCF when forecasts are reliable; use comps when public peers are tight; use precedents to test market appetite and control premia.
• Suggested starting weights: DCF 40%, comps 35%, precedents 25%, then revise based on deal specifics and data quality.

Transaction accounting and modeling mechanics

You're building deal models to turn offer terms into pro forma financials; direct takeaway: compute enterprise value precisely, run a defensible purchase price allocation, build realistic debt schedules with covenant checks, and flow every PPA and financing effect through pro forma statements so the board sees EPS, leverage, and cash impact.

Compute enterprise value and perform the purchase price allocation

Start by reconciling market metrics and deal economics. Compute enterprise value (EV) as: equity purchase price plus net debt plus minority interest plus preferred. Example FY2025 inputs: market equity value (market cap) $1,000,000,000, net debt $200,000,000, minority interest $25,000,000, preferred $0 → implied EV $1,225,000,000. If you pay a control premium (common ~20-40%), show the purchased equity price separately: 30% premium on $1.00B → equity purchase $1.30B, enterprise purchase price = equity purchase + net debt = $1.50B.

Run the purchase price allocation (PPA) immediately after closing. Steps: (1) list fair value of tangible net assets (PPE, inventory, receivables) - example $300,000,000; (2) value identifiable intangibles (customers, technology, trademarks) - example finite-lived intangibles $350,000,000; (3) record deferred tax liabilities on step-ups (use combined tax rate; example 25%: DTL = $87,500,000); (4) compute goodwill as enterprise purchase price minus fair value net identifiable assets after DTL. Quick math here: fair value assets = $650,000,000; after DTL = $562,500,000; goodwill = $937,500,000.

Best practices: get third‑party valuations for material intangibles, document useful lives (finite vs indefinite), map tax amortization (Section 197 in US: 15 years for many intangibles), and follow ASC 805 for US GAAP PPA rules. What this estimate hides: timing of tax benefits, contingent liabilities, and any earnout mechanics that alter final goodwill-model multiple outcomes.

Reflect financing: structure debt, interest, amortization, and covenant checks

Model financing in two layers: cash uses/ sources at close, then ongoing debt service. At close, reconcile: purchase price paid to sellers, assumed net debt, deal fees, and working capital true-up. Example close sources for the $1.50B enterprise purchase: acquirer cash contribution $600,000,000, new term debt $700,000,000, no equity issuance in this example. New post-close net debt roughly $900,000,000 (existing net debt $200M + new debt $700M - cash acquired).

Build debt schedules with these columns: opening balance, draws/repayments, interest rate, cash interest, non‑cash amortization of financing fees, and closing balance. Use realistic terms: senior tranche coupon 7.5%, subordinated tranche 10.0%, contractual amortization 5% per annum with bullet maturity. Example blended cost of debt 8.0% → cash interest year 1 on $900M = $72,000,000. Show sensitivity to rate moves ±200 bps.

Embed covenant calculations on a rolling basis: leverage (Net Debt / LTM EBITDA) and interest coverage (EBITDA / cash interest). Example FY2025 target LTM EBITDA $150,000,000 → post‑deal leverage = 6.0x, interest coverage = 2.08x. Flag breaches versus typical covenant thresholds (leverage 4.5x, coverage > 3.0x). If breached, model covenant cures: amortization acceleration, equity cures, or covenant waiver fees. defintely stress-test covenant headroom under downside scenarios.

Build flow-through schedules: pro forma balance sheet, income statement, and cash flow

Linking mechanics: start with standalone FY2025 financials for acquirer and target, then apply transaction adjustments that flow through three statements. Typical adjustments: elimination entries (intercompany), cash consideration and financing, PPA fair‑value amortization and depreciation, goodwill, transaction and financing fees, and tax effects. Model each adjustment as a bridge line item with a clear accounting tag (e.g., PPA amortization - expense; financing fees - deferred asset amortized via effective interest).

Example PPA flow-through numbers: finite intangible step-up $350,000,000 amortized over 10 years → annual amortization $35,000,000; PPE step-up $50,000,000 over 10 years → $5,000,000 depreciation. Those increase D&A, reduce operating income, and change taxable income. Apply tax rate 25% to compute cash tax effects and DTAs/DTLs. Goodwill $937,500,000 is not amortized under US GAAP; model annual impairment testing scenarios instead.

Cash flow statement: start with pro forma net income, add back non‑cash PPA amortization/depreciation, adjust for cash interest paid per debt schedule, subtract cash taxes, and include capex and working capital changes. Show free cash flow to firm (FCFF) and equity (FCFE) side-by-side. For EPS and accretion/dilution, model share count changes if equity is issued; example: if $300,000,000 equity consideration issued at $50/share → 6,000,000 new shares; compute pro forma net income per share and run year 1 and year 3 accretion tests.

Best practices and checks: tie working capital, fixed assets, and cash to the pro forma balance sheet; reconcile retained earnings movement to net income minus dividends; report a one‑page sensitivity deck showing EPS, leverage, and ROIC under key scenarios. Immediate next step: Finance: build deal model base case and three sensitivities by Thursday; M&A lead: coordinate DD materials.

Accretion/dilution, sensitivities, and break-even analysis

You're running deal models to prove whether the transaction helps or hurts EPS - direct takeaway: calculate a clean pro forma EPS across financing and price scenarios, then show where the deal is accretive, dilutive, or indifferent.

Models should give the board clear yes/no outputs at the EPS line and the levers that move it.

Calculate pro forma EPS and run accretion/dilution across pricing, mix, and financing scenarios

Steps to build a defensible pro forma EPS:

• Start with standalone metrics: use acquirer FY2025 net income and diluted shares. Example: acquirer net income $1,200m, diluted shares 600m, standalone EPS $2.00.
• Add target FY2025 net income: example target net income $150m (combined pre-synergy total = $1,350m).
• Incorporate synergies after tax: after-tax synergies = synergy × (1 - tax rate). Example tax rate 25%: a $50m synergy → after-tax benefit $37.5m.
• Include financing costs: new debt interest reduces pre-tax income; after‑tax impact = interest × (1 - tax rate). Example 6% new debt on a $2,000m cash purchase → interest $120m, after-tax $90m.
• Adjust for PPA (purchase price allocation): amortizable step‑up reduces accounting earnings; goodwill does not amortize under GAAP. Example intangible amortization $20m pre-tax → after-tax impact $15m.
• Compute pro forma EPS: (acquirer NI + target NI + after-tax synergies - after-tax interest - after-tax amort) / pro forma diluted shares.
• Compare to standalone EPS and report accretion % = (pro forma EPS / standalone EPS - 1) × 100.

Example quick math, cash-financed: combined NI = $1,350m + $37.5m - $90m = $1,297.5m. EPS = 1,297.5 / 600 = $2.1625 → accretion ≈ +8.1%. What this hides: PPA amort, one-time fees, and revenue retention assumptions.

Build sensitivity tables for price paid, synergies, cost of debt, and revenue retention

Practical setup and best practices:

• Build a 2D sensitivity matrix with purchase price on one axis and synergy run‑rate on the other. Show accretion % in each cell and flag the break-even line.
• Layer financing scenarios: all-cash, cash+debt (show interest), and all-stock (show share issuance and dilution).
• Include revenue retention (customer attrition) as a multiplier on target EBITDA/earnings - model 70%, 90%, 100% retention scenarios.
• Stress test cost of debt by ±200 bps; show EPS impact per 100 bps to quantify rate sensitivity.

Quick sensitivity math: each +1% in cost of debt on a $2,400m loan adds $24m pre‑tax interest → after‑tax ≈ $18m net income hit → EPS drop ≈ $0.03 on 600m shares. Revenue retention: losing 10% of target revenue roughly reduces target NI by 10% (and raises the required synergy to remain accretive).

Solve break-even synergies and payback period and flag key KPIs

How to solve break-even synergies (EPS-accretive):

• Set pro forma EPS = acquirer standalone EPS and solve for synergy S. For cash deal with unchanged shares the formula simplifies to: 0.75×S = standalone NI - (acquirer NI + target NI) + 0.75×interest.
• Using our example numbers: required S = -$200m + interest. For a $2,000m deal (interest = $120m) break-even S = -$80m (i.e., accretive even with zero synergies).
• For stock deals include new shares: break-even requires solving (A + T + 0.75S - 0.75I) / Shares_new = A / Shares_old; rearrange to solve S.

Payback period on synergies (straight cash payback) = purchase price / annual after-tax synergies. Example: $2,000m / ($50m × 0.75 = $37.5m) → payback ≈ 53 years. That highlights a common reality: synergies alone often do not justify price - you need earnings contribution, multiple arbitrage, or significant operational upside.

Key KPIs to track and report in every accretion/dilution deck:

• Leverage ratio: net debt / run‑rate EBITDA. Target post‑deal <3.5x for public peers, <6.0x for LBO ranges.
• Interest coverage: EBIT / interest expense; aim for > 3.0x to avoid covenant pressure.
• ROIC (return on invested capital) vs WACC: deal should raise ROIC above WACC within the integration horizon.
• Synergy realization cadence: % realized at 12, 24, 36 months (example cadence: 30% / 70% / 100%).

Due diligence, integration planning, and risks




You're running deal diligence to convert a strategic idea into executable numbers - quick takeaway: focus on earnings quality, realistic integration costs, and a quantified execution-risk overlay so the board can pick a price with eyes open.

Financial due diligence




Takeaway: validate the cash that really exists today and the recurring profit run-rate you can depend on.

Steps to run Quality of Earnings (QoE):

• Reconcile GAAP net income to cash EBITDA; adjust for non-recurring items and owner-related expenses.
• Validate revenue recognition by contract, backlog, and seasonality; sample 12-24 large contracts.
• Test margin drivers: gross margin by product, customer, and channel for the last 12-36 months.



Working capital normalization - practical math: normalize to a target NWC days (days sales outstanding + inventory days - days payables). Example: target revenue $500 million, buyer NWC target 25 days, seller run-rate 35 days → cash shortfall = $500m / 365 × 10 = $13.7m. Always show this as a one-time cash true-up in the purchase agreement.

Tax and contingent liability checks:

• Review deferred tax assets/liabilities, NOL (net operating loss) limitations, transfer pricing, and VAT exposure.
• Quantify legal contingencies as probable (reserve now) versus possible (disclose only); push for escrows or reps & warranties insurance when exposure > 1-3% of deal value.
• Use escrow/holdback ranges of 5-10% of purchase price for 12-24 months as a negotiating anchor.



Best practice: produce a QoE memo with a reconciled EBITDA bridge, an explicit working capital true-up schedule, and a prioritized list of tax and legal exposures with recommended reserves.

Operational due diligence and integration planning




Takeaway: measure the cost and tempo of change - integration costs bite early, revenue retention matters longer.

Core operational checks:

• Audit customer concentration and churn trends; stress-test scenarios where top 5 customers reduce spend by 10-30%.
• Map IT estate, data flows, and third-party SaaS contracts; flag single-vendor dependencies and cross-border data risks.
• Inventory people risk: identify 20-30 key roles, current comp, and potential retention cost.



Estimate integration cost and timing with examples: for a combined company with $1 billion revenue, plan one-time integration spend of 1-3% of revenue ( $10-$30m ) for systems, severance, and advisory; ERP consolidation commonly takes 9-18 months and can cost $5-$15m for mid-market targets.

Customer churn math example: if target revenue is $200m and you lose 5% of revenue in year one due to integration, that's a $10m revenue hit; capture that in the base-case and downside scenarios.

Integration governance - actionable steps:

• Stand up an Integration PMO with an owner, weekly milestones, and a two-page integration charter.
• Create a 100‑day plan for retention, systems cuts, and top-10 customer outreach.
• Set a dedicated synergy tracking ledger with monthly verification and named owners.



One-liner: treat integration like a product launch - time-boxed, resourced, and measured.

Regulatory, antitrust, and execution risk quantification




Takeaway: quantify the chance and cost of regulatory delays, remedies, and execution failure, then bake those into price and reserves.

Regulatory process and likely timelines to model:

• US Hart-Scott-Rodino (HSR) statutory waiting period: typically 30 calendar days (unless early termination).
• EU Commission: Phase I ≈ 25 working days; Phase II (in-depth) ≈ 90 working days.
• Remedies often include divestitures or behavioral commitments; model their valuation impact and timing drag on synergy capture.



Modeling remedies and deal certainty:

• Assign probabilities to clearance, conditional clearance, or prohibition and compute an expected deal value adjustment.
• If divestiture is likely, value the divestiture gap (price minus expected buyer value) and include transaction costs and lost synergies.



Quantifying execution risk with probability-weighted scenarios - example math:

Stated synergy target = $120m. Build three scenarios and probabilities: base 60% (realize 70% = $84m), downside 30% (realize 40% = $48m), upside 10% (realize 100% = $120m). Expected synergies = 0.6×84 + 0.3×48 + 0.1×120 = $76.8m.

Apply a contingency buffer: reserve 10-25% of expected synergies for execution risk and timing; in the example a 15% buffer reduces actionable synergies to $65.3m.

Decision rules and covenant checks:

• Set post-close leverage targets (net debt/EBITDA) and hard covenant triggers - common mid-market anchor: ≤4.0x net debt/EBITDA for conservative buyers; PE owners may accept 4.5-6.0x.
• Model interest coverage and liquidity under stress (e.g., revenue -10% and synergies -30%).
• Use escrow, earnouts, and RWI (representations & warranties insurance) to allocate execution and legal risk.



One-liner: convert qualitative execution worries into dollar reserves and probability-weighted adjustments so the board sees the true net economic benefit - and defintely stress-test the weakest link.

Immediate next step: Finance: build the deal base-case model, plus three probability-weighted sensitivity scenarios (base/downside/upside) and an integration cash budget by Thursday; M&A lead: deliver QoE report, top-30 customer list, and IT risk map by Wednesday.




Conclusion




Present decision-ready outputs: what the board needs on the table




You're taking this to the board and they need crisp, comparable answers not slides full of noise. One-liner: give the board a clear valuation range, the expected EPS impact, and the integration P&L so they can trade risk versus reward in a single meeting.

Produce these core deliverables as files the board can read in 10 minutes:

• Valuation range: DCF, comps, precedents with mid, low, high. Example: EV range $800m-$1.2bn (FY2025 base case), show implied price per share.
• Accretion/dilution matrix: price paid x financing mix x synergy cadence. Example: acquirer EPS $2.50, pro forma EPS year 1 $2.70 = 8% accretion.
• Integration P&L: detailed cost-to-achieve, one-time vs run-rate, and projected synergy capture by quarter for 36 months.
• Sensitivity decks: 3× scenario pages (base, downside, upside) plus a two-way table for price vs synergy.



Here's the quick math for the board slide: show NPV of synergies, payback period, and IRR at the midpoint price. What this estimate hides: integration slippage, tax timing, and retention clawbacks - call them out on the same slide so the board can see trade-offs at a glance.

Frame trade-offs: single-slide decision mechanics




You want the board to choose with eyes open. One-liner: summarize trade-offs with three clear metrics - value creation (NPV/IRR), dilution (EPS change), and execution risk (probability-weighted loss).

Concrete steps to build that slide:

• Calculate NPV and IRR on FY2025 cash flows using a clear WACC and tax assumptions; display NPV at midpoint price and sensitivity to ±25% synergies.
• Produce an EPS waterfall showing acquisition accounting, interest expense, and synergy run-rate to year 1 and year 3.
• Quantify break-even synergies: solve for synergy level that makes the deal EPS-accretive in year 1 and year 3. Example: break-even $45m in run-rate synergies to be accretive year 1 at midpoint price.
• Score execution risk: assign probabilities (high/med/low) and compute probability-weighted NPV; show contingency buffers (e.g., 20% haircut on synergies if post-close churn >10%).



One clean visual wins: a 3-box chart (value upside vs dilution vs risk) with recommended board vote highlighted. Still, include the underlying numbers in an appendix for any director who wants to dig in - don't hide the math.

Immediate next steps and owners: fast, concrete execution checklist




You need executable actions with owners and deadlines. One-liner: convert the board package into a 72‑hour operational sprint so the deal either moves or dies quickly.

Action list (start now):

• Finance: build the deal model base case and three sensitivities (downside, base, upside) using FY2025 actuals; deliver by Thursday. Include pro forma BS/IS/CF and covenant tests.
• M&A lead: coordinate due diligence (financial, tax, legal, commercial) and collect DD room materials; confirm access and timeline by EOD tomorrow.
• Treasury: prepare financing term sheet scenarios - cash-only, mixed debt, and issuer equity - with all-in cost and amortization schedule.
• Integration lead: draft 100-day integration plan, list top 10 integration risks, and estimate one-time costs and run-rate savings by quarter.
• Legal & Tax: draft preliminary purchase agreement points, note tax step-up and potential indemnities; flag regulatory filings required and expected timeline.



Quick math for the sprint: a 13-week cash view will show if financing and synergies bridge the immediate funding gap; if onboarding takes >14 days, churn and cost overruns rise materially. Finance: build the deal model base case and three sensitivities by Thursday; M&A lead: coordinate DD materials.






All DCF Excel Templates

5-Year Financial Model

40+ Charts & Metrics

DCF & Multiple Valuation

Free Email Support

DOWNLOAD




Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.